drugset
drugset / Trial / NCT04706949

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

NCT04706949 ↗

Phase 2 Unknown 26 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or amplified recurrent / metastatic non-small cell lung cancer

Timeline

Start
2020-12-07
Primary completion
2021-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — —
Subject Pemetrexed Small molecule 500 mg/m2 —
Subject Pyrotinib Small molecule 400 mg Oral

Indications

non-small cell lung carcinoma